NPI: 1245259878 · WABASH, IN 46992 · General Acute Care Hospital · NPI assigned 07/18/2006
Authorized official RISSER, STANTON controls 20+ related entities in our dataset. Read more
| Authorized Official | RISSER, STANTON (ACFO) |
| NPI Enumeration Date | 07/18/2006 |
Other providers sharing the same authorized official: RISSER, STANTON
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 12,875 | $190K |
| 2019 | 12,472 | $344K |
| 2020 | 10,739 | $433K |
| 2021 | 20,202 | $1.02M |
| 2022 | 22,539 | $1.26M |
| 2023 | 30,342 | $1.92M |
| 2024 | 17,101 | $1.24M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 16,866 | 13,794 | $2.72M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 8,072 | 5,904 | $970K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2,740 | 1,919 | $546K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 5,918 | 1,214 | $311K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,874 | 2,928 | $244K |
| 71045 | Radiologic examination, chest; single view | 1,854 | 1,444 | $236K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 598 | 455 | $139K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,608 | 1,347 | $102K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,676 | 968 | $81K |
| 80048 | Basic metabolic panel (calcium, ionized) | 13,506 | 10,096 | $80K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 456 | 398 | $80K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 13,297 | 10,391 | $78K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 863 | 110 | $72K |
| 71046 | Radiologic examination, chest; 2 views | 420 | 367 | $67K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 175 | 140 | $66K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2,296 | 1,867 | $60K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 653 | 145 | $56K |
| 36415 | Collection of venous blood by venipuncture | 17,082 | 13,238 | $42K |
| 80076 | 6,661 | 5,244 | $39K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 1,524 | 1,074 | $32K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 433 | 401 | $30K |
| 96361 | Intravenous infusion, hydration; each additional hour | 771 | 624 | $27K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 371 | 275 | $24K |
| 90834 | Psychotherapy, 45 minutes with patient | 292 | 153 | $23K |
| 83605 | 2,418 | 1,795 | $20K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 755 | 665 | $19K |
| 99221 | 29 | 25 | $18K | |
| 90791 | Psychiatric diagnostic evaluation | 205 | 153 | $17K |
| 81001 | 3,976 | 3,191 | $14K | |
| 80050 | General health panel | 99 | 93 | $13K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 392 | 352 | $12K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 103 | 97 | $11K |
| 84484 | 1,215 | 834 | $11K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1,163 | 1,055 | $11K |
| 83690 | 2,388 | 1,924 | $11K | |
| 99217 | 32 | 24 | $10K | |
| 90832 | Psychotherapy, 30 minutes with patient | 126 | 64 | $9K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 328 | 296 | $8K |
| 80061 | Lipid panel | 1,013 | 901 | $7K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15 | 12 | $7K |
| 99238 | Hospital discharge day management, 30 minutes or less | 13 | 12 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 152 | 137 | $7K |
| 80053 | Comprehensive metabolic panel | 1,076 | 973 | $6K |
| 83735 | 687 | 544 | $5K | |
| 99219 | 16 | 12 | $5K | |
| 84439 | 835 | 759 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 427 | 395 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | 982 | 874 | $4K |
| 80305 | 374 | 289 | $4K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 51 | 45 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 461 | 376 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | 32 | 25 | $3K |
| 85027 | 651 | 472 | $3K | |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 73 | 49 | $2K |
| 82607 | 151 | 140 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 108 | 68 | $2K |
| 82746 | 103 | 96 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 33 | 29 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 29 | 25 | $1K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 955 | 677 | $1K |
| 87634 | 20 | 16 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 27 | 25 | $1K |
| 82150 | 451 | 370 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 387 | 321 | $1K |
| 81003 | 353 | 306 | $1K | |
| 85379 | 121 | 92 | $755.35 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 46 | 39 | $737.13 |
| 87081 | 133 | 123 | $735.89 | |
| 87040 | 99 | 51 | $629.69 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 75 | 67 | $586.20 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 35 | 24 | $569.56 |
| 82962 | 105 | 37 | $532.03 | |
| 84460 | 104 | 86 | $238.99 | |
| 86592 | 42 | 40 | $155.98 | |
| 81025 | 13 | 13 | $94.71 | |
| 96376 | 77 | 24 | $85.48 | |
| 80051 | 17 | 16 | $54.61 | |
| 82565 | 17 | 16 | $39.91 | |
| 84520 | 17 | 16 | $30.76 | |
| 82553 | 14 | 12 | $19.43 | |
| 82550 | 15 | 13 | $18.64 | |
| 85730 | 20 | 18 | $14.40 | |
| 85610 | 20 | 18 | $9.40 | |
| A9270 | Non-covered item or service | 52 | 28 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 139 | 119 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 20 | 12 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 277 | 248 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 102 | 71 | $0.00 |